HOME › DRUGS › IDELALISIB
ACTIVE SUBSTANCE / INN

IDELALISIB

Brand name(s): ZYDELIG, IDELALISIB, Zydelig
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
ANDA216921
Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell
ACTIVE SUBSTANCE
Idelalisib
REGULATORS
FDA · EMA
SPONSORS / MAH
NATCO, GILEAD SCIENCES INC, Gilead Sciences Ireland UC
TOTAL APPLICATIONS
3
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
IDELALISIBANDA216921NATCOPrescription
ZYDELIGNDA205858GILEAD SCIENCES INCPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ZydeligGilead Sciences Ireland UCAuthorised18/09/2014Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell

FULL INTELLIGENCE ON IDELALISIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →